Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  OrganiGram Holdings Inc    OGI   CA68620P1018

ORGANIGRAM HOLDINGS INC (OGI)
My previous session
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Financials (CAD)
Sales 2018 14,4 M
EBIT 2018 2,09 M
Net income 2018 -1,00 M
Debt 2018 123 M
Yield 2018 -
Sales 2019 117 M
EBIT 2019 27,4 M
Net income 2019 23,2 M
Finance 2019 138 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 49,93
EV / Sales2018 71,6x
EV / Sales2019 6,59x
Capitalization 909 M
More Financials
Company
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana.Through Organigram Inc., its main focus is on the production of condition specific medical marijuana for patients in Canada.The company was founded on August 22, 2014 and is headquartered in Moncton, Canada. 
Sector
Pharmaceuticals
Calendar
12/19Earnings Release
More about the company
Surperformance© ratings of OrganiGram Holdings Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on ORGANIGRAM HOLDINGS INC
09/14ORGANIGRAM : signs supply agreement with Newfoundland and Labrador Liquor Corpor..
AQ
09/14ORGANIGRAM : Update on Proposed Investment in European CBD Hemp Producer Eviana
AQ
09/13Global Cannabis Partnership Welcomes New Members
AQ
09/13EVIA HEAL : Eviana Announces Proposed $10 Million Debenture Offering
AQ
09/13ORGANIGRAM : invests in Hyasynth Biologicals Inc., helps bring transformative "c..
AQ
09/12ORGANIGRAM : Chosen to Include Award-Winning Sativa Flower, Wabanaki, in World's..
AQ
09/10Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Onco..
AC
09/06ORGANIGRAM : OTC Markets Group Welcomes Organigram Holdings, Inc. to OTCQX
PR
09/06ORGANIGRAM : Announces Trading on the OTCQX® Best Market
AQ
08/31ORGANIGRAM : Announces the Issuance of RSU Awards
AQ
More news
Sector news : Alternative Medicine
11:56aGILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
08:15aSHIRE : Rule 2.9 Announcement
DJ
08:03aAstraZeneca plots China robot offensive to counter price cuts
RE
07:08aAstraZeneca plots China robot offensive to counter price cuts
RE
07:02aBAYER : Monsanto asks U.S. court to toss $289 mln glyphosate verdict
RE
More sector news : Alternative Medicine
News from SeekingAlpha
09/17Jonathan Cooper Portfolio Review, September 2018 
09/03WEEKLY CANNABIS REPORT : "Be Fearful When Others Are Greedy!" 
08/29THE BIGGEST RISK FOR CANOPY GROWTH : Oversupply 
08/29Tilray In 2 Words; Sell It. It Is Trading At 156x Forward Sales 
08/28THE CANNABIS CHRONICLES : Possible Cannabis Bubble And Nova Scotia Supply Agreem.. 
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 7,47  CAD
Spread / Average Target 3,2%
EPS Revisions
Managers
NameTitle
Greg Engel Chief Executive Officer & Non-Independent Director
Peter Amirault Chairman
Jeff Purcell Vice President-Operations
Paolo de Luca Chief Financial Officer
Kenneth Mitton Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ORGANIGRAM HOLDINGS INC697
CANOPY GROWTH CORP126.40%11 073
AURORA CANNABIS INC14.79%7 279
BEIJING TONGRENTANG CO., LTD.-6.85%5 877
DONG-E-E-JIAO CO LTD--.--%4 156
HUTCHISON CHINA MEDITECH LIMITED-22.32%3 782